Jade Biosciences Secures Exclusive Worldwide License for New Therapeutic Program JADE301
JBIO has more than doubled off its 52-week low of $6.67.
Summary
Jade Biosciences entered into an exclusive, worldwide license agreement with Paragon Therapeutics for a new therapeutic program, JADE301, involving potential milestone payments and royalties.
Key Events · Product Development and Regulatory · JBIO
-
Exclusive Worldwide License
Jade Biosciences obtained an exclusive, sublicensable, worldwide license from Paragon Therapeutics for monospecific antibodies targeting an undisclosed target (JADE301) across all therapeutic areas.
-
Milestone Payments and Royalties
The agreement includes up to $22.0 million in development and regulatory milestones, with $1.5 million already paid in January 2026 and $2.5 million due upon Phase 1 dosing. Additionally, up to $20.1 million in sublicensing fees and low to mid-single-digit percentage royalties on net sales are stipulated.
-
Pipeline Expansion
This license adds a new therapeutic candidate, JADE301, to the company's pipeline, diversifying its drug development efforts beyond existing programs like JADE101.
Analysis · JBIO · Life Sciences
This agreement significantly expands Jade Biosciences' drug development pipeline by adding a new, exclusive therapeutic candidate, JADE301. While it entails future milestone payments and royalties, these are tied to successful development and commercialization, indicating potential for long-term growth and diversification of their product portfolio. This follows recent positive Phase 1 results for their JADE101 program, suggesting continued strategic investment in their therapeutic assets.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JBIO was trading at $21.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $6.67 to $28.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.